Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: August 19, 2026
Principal Executive Office: Marseille, France
This filing reports the completion of a private placement capital increase without preferential subscription rights, executed pursuant to resolutions passed at the combined shareholders' meeting on May 21, 2026.
Key Financial Metrics
| Metric | Value |
|---|---|
| Gross Proceeds | €30.0 million |
| Shares Issued | 17,647,059 ordinary shares |
| Issue Price | €1.70 per share |
| Estimated Offering Expenses | €2.4 million |
| Net Proceeds | €27.6 million |
Note: The filing does not provide data on revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
- Capital Structure: The Company issued 17,647,059 new ordinary shares, increasing its share capital.
- Liquidity: The transaction generated approximately €27.6 million in net cash proceeds.
- Lock-up Restrictions: Board members (excluding Bpifrance Participations), certain executive officers, and the Company itself agreed to 90-day contractual lock-up restrictions on existing shares following the offering completion.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to prioritize the continued clinical development of IPH4502, based on dose escalation results. Remaining funds will support the advancement of the preclinical ADC portfolio candidates, working capital, and general corporate purposes.
Offering Structure: The offering was conducted via two tranches:
- 4(a)(2) Tranche: Sold to qualified institutional buyers in the U.S. under Section 4(a)(2) of the Securities Act.
- Regulation S Tranche: Sold to qualified investors in the EU and outside the EU under Regulation S.
Listing Status: Offered shares are approved for listing on Euronext Paris under the existing trading line (ISIN: FR0010331421). No new American Depositary Shares (ADSs) were issued, and offered shares cannot be deposited into the existing ADS program.
Investor Verification Checklist
- Verify the final dilution impact of the 17,647,059 new shares on existing shareholders.
- Confirm the specific clinical milestones for IPH4502 that will be funded by the €27.6 million net proceeds.
- Review the full text of the U.S. Subscription Agreement (Exhibit 99.1) for specific covenants and representations.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check subsequent filings for updates on the preclinical ADC portfolio advancement.